Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

NCT06180863 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of funding.

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: oral azacitidine (CC-486)

Sponsor

Yale University

Collaborators

[object Object]
[object Object]